BeiGene Ltd said on Monday a late-stage trial failed to show that its cancer tre...
- BeiGene Ltd said on Monday a late-stage trial failed to show that its cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc. The results come merely a month after BeiGene scored a win with Brukinsa’s approval to treat patients with mantle cell lymphoma, who have received at least one prior therapy.
“It is unlikely that we would do other trials, I think that there’s potential that with longer follow up this trial in and of itself could suffice,” Eric Hendrick, chief adviser at BeiGene, told Reuters. Like Imbruvica, Brukinsa belongs to a class of drugs called Bruton’s tyrosine kinase inhibitors. It also competes against AstraZeneca Plc’s Calquence, another BTK inhibitor.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Stress, Sadness Really Can Break Your HeartBroken heart syndrome doesn't just happen after a loved one or a pet dies. Medical treatments, job loss, and other major life stressors have been linked to the condition too.
Leer más »
'Project Runway' Recap: Order It Animal StyleProject Runway Season 18, Episode 2 Recap: Order It Animal Style
Leer más »
H&M's recovery continues as fourth quarter sales jump 9%Fashion retailer H&M said on Monday its sales rose 9% in the fourth quarter, put...
Leer más »
H&M's sales grow 5% in fourth-quarter in local currenciesSweden's H&M , the world's second-biggest fashion retailer, reported o...
Leer más »
Women Need To Be ‘Liked’ To Advance At Work, But Men Can Be Total A-holesA study finds that women must be nice to be influential at work.
Leer más »
Survey Says 30’s Is ’Too Old’ To Club, Moms Say ‘Whatever, I’m Too Tired Anyway’British study says 37 is too old to go clubbing.
Leer más »